JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hicks, K. O.
Right arrow Articles by Wilson, W. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hicks, K. O.
Right arrow Articles by Wilson, W. R.

Vol. 297, Issue 3, 1088-1098, June 2001

Extravascular Transport of the DNA Intercalator and Topoisomerase Poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): Diffusion and Metabolism in Multicellular Layers of Tumor Cells

Kevin O. Hicks, Frederik B. Pruijn, Bruce C. Baguley and William R. Wilson

Auckland Cancer Society Research Centre, Faculty of Medicine and Health Sciences, The University of Auckland, Auckland, New Zealand

There is considerable evidence that DNA intercalating drugs fail to penetrate tumor tissue efficiently. This study used the multicellular layer (MCL) experimental model, in conjunction with computational modeling, to test the hypothesis that a DNA intercalator in phase II clinical trial, N-[2-(dimethylamino)-ethyl]acridine-4-carboxamide (DACA), has favorable extravascular transport properties. Single cell uptake and metabolism of DACA and the related but more basic aminoacridine 9-[3-(dimethylamino)propylamino]acridine (DAPA), and penetration through V79 and EMT6 MCL, were investigated by high-performance liquid chromatography. DACA was accumulated by cells to a lesser extent than DAPA and was metabolized to the previously unreported acridan by V79 but not EMT6 cells. Despite this metabolism, flux of DACA through MCL was much faster than that of DAPA. Modeling MCL transport as diffusion with reaction (metabolism and reversible binding) showed that the faster flux of DACA was due to a 3-fold higher free drug diffusion coefficient and 10-fold lower binding site density. The MCL transport parameters were used to develop a spatially resolved pharmacokinetic model for the extravascular compartment in tumors, which provided a reasonable prediction of measured average tumor concentrations from plasma pharmacokinetics in mice. Area under the curve was essentially independent of distance from blood vessels, although the combined pharmacokinetic/pharmacodynamic model predicted a modest decrease in cytotoxicity (from 1.8 to 1.1 logs of cell kill) across a 125-µm region. In conclusion, this study demonstrates that it is possible to design DNA intercalators that diffuse efficiently in tumor tissue, and that there is little impediment to DACA transport over distances required for its antitumor action.

0022-3565/01/2973-1088$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 aacredbookHome page
W. R Wilson, K. O Hicks, F. B Pruijn, and A. V Patterson
Targeting Tumor Hypoxia with Prodrugs: Challenges and Opportunities
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 293 - 310.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
O. Tredan, C. M. Galmarini, K. Patel, and I. F. Tannock
Drug Resistance and the Solid Tumor Microenvironment
J Natl Cancer Inst, October 3, 2007; 99(19): 1441 - 1454.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
K. O. Hicks, F. B. Pruijn, T. W. Secomb, M. P. Hay, R. Hsu, J. M. Brown, W. A. Denny, M. W. Dewhirst, and W. R. Wilson
Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs.
J Natl Cancer Inst, August 16, 2006; 98(16): 1118 - 1128.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. G. Siim, F. B. Pruijn, J. R. Sturman, A. Hogg, M. P. Hay, J. M. Brown, and W. R. Wilson
Selective Potentiation of the Hypoxic Cytotoxicity of Tirapazamine by Its 1-N-Oxide Metabolite SR 4317
Cancer Res., January 15, 2004; 64(2): 736 - 742.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. H. Kyle, L. A. Huxham, J. H. E. Baker, H. E. Burston, and A. I. Minchinton
Tumor Distribution of Bromodeoxyuridine-labeled Cells Is Strongly Dose Dependent
Cancer Res., September 15, 2003; 63(18): 5707 - 5711.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. O. Hicks, F. B. Pruijn, J. R. Sturman, W. A. Denny, and W. R. Wilson
Multicellular Resistance to Tirapazamine Is Due to Restricted Extravascular Transport: A Pharmacokinetic/Pharmacodynamic Study in HT29 Multicellular Layer Cultures
Cancer Res., September 15, 2003; 63(18): 5970 - 5977.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. R. Wilson, S. M. Pullen, A. Hogg, N. A. Helsby, K. O. Hicks, and W. A. Denny
Quantitation of Bystander Effects in Nitroreductase Suicide Gene Therapy Using Three-Dimensional Cell Cultures
Cancer Res., March 1, 2002; 62(5): 1425 - 1432.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.